logo
17 Best Cooling Sheets

17 Best Cooling Sheets

Buzz Feed02-07-2025
Hi, all my fellow hot sleepers!!! Tell your night sweats they're about to meet their match — we've found sheet sets that are actually cooling and won't make your bed feel like a sauna in the summer.
So what did we look for when finding these 15 reviewer-loved sheet sets? 100% cotton and 100% linen reign supreme when it comes to cooling fabrics. Cotton is lightweight and breathable, and linen ups the ante by also being moisture-wicking. However, cotton is very durable (especially long- or extra-long staple cotton like Supima), while linen is less so.We also included a mix of sateen- and percale-weave sheets. Sateen sheets are super smooth, drape easily, and have a subtle sheen to them. Percale sheets have more of a crisp, cool feeling with a matte finish — think of a freshly laundered shirt! We'll also point out if the set is Oeko-Tex certified. This means it has been independently tested for harmful substances to ensure that it is suitable for humans to use — that's super important for something that makes contact with your skin on a nightly basis!We decided not to include bamboo sheets, as most of them undergo less sustainable production methods. Most sheets that advertise themselves as "bamboo" are actually made of bamboo-viscose (aka bamboo-rayon) or bamboo-lyocell, which are produced in ways that involve toxic chemicals that can become pollutants. You can read more about bamboo fabrics at The Council of Fashion Designers of America.Oh, and microfiber is not the best choice when it comes to staying cool. It's tightly-woven, meaning your body heat won't escape as easily.Okay, now let's find you a new sheet set!!!
A wildly popular 400-thread count cotton sateen cooling sheet set so soft and cooling, you'll never throw them off you in the middle of the night when you suddenly feel like someone cranked up the thermostat to 100 degrees. Bonus — reviewers say these hold up super well after repeated washings with very few wrinkles and no shrinkage!
A 100% European linen set that comes in a gingham pattern so country-chic it might just mentally transport you to a cozy cabin in the woods. Reviewers rave over them for their super lightweight feel. (Oh, and that there's an option without a flat sheet!)
A set made with 100% Egyptian cotton in a percale weave — which is perfect for curling up under on a 90+ degree day while watching Uptown Girls and singing along to 🎶na na na na na na na na, sheets of Egyptian cotton. 🎶 Oh, and Egyptian cotton is known for its durability, so these should last you for years to come.
A set of 100% organic cotton sheets that come packaged in a reusable fabric bag, which is so much better than the flimsy plastic other sets come in. Several reviewers say these are thin enough to feel comy for hot sleepers, yet sturdy enough to stand up to many washes — one reviewer says years worth!
A splurge-worthy set of Supima cotton sheets with a super smooth sateen weave that'll tell night sweats to take a hike. One reviewer even compared these to hotel sheets, which is truly the highest compliment you can give to a sheet set.
A set of 100% cotton sateen sheets that are BELOVED by Target reviewers. No, really, I think some of these reviewers are counting on these becoming a family heirloom. That's probably because of the smooth 400-thread count wrinkle-resistant fabric, and the extremely helpful "top or bottom" tags so you know which side is which. If you've ever almost given up on making your bed and just flopping on the couch because you lined the fitted sheet's corners up incorrectly, these are for you.
A Brooklinen cotton set with a percale weave — it comes with one flat sheet and two pillowcases, so it's perfect for anyone who sweats at the mere thought of using a flat sheet. The brand says it's meant to feel "like your fave button-down shirt," and I can't think of anything cozier. Plus, each side is labeled with "long" and "short," which should honestly be a legal requirement for all sheet sets.
A Miracle Made sheet set made with 100% cotton in a crisp-feeling percale weave that's infused with silver — but it would absolutely take home the gold in the Cooling Sheet Olympics. Why would you want silver in your sheets? Silver has antibacterial properties, which may help cut down on the amount of bacterial growth. No, that doesn't necessarily mean you need to wash these less, but it might give you some peace of mind while you drift off the dreamland.
A pure linen set so buttery smooth you'll roll around on it like a dog going carpet swimming. It's designed to absorb moisture without feeling wet to the touch, so if night sweats come to pay you a visit, they'll be quickly whisked away with barely a trace.
A set made with 100% pima cotton (meaning they're luxuriously soft, silky, and long-lasting compared to regular cotton fibers) and a percale weave for a crisp, cool feel and matte finish. And can we talk about the floral prints?! Absolutely stunning for any time of the year = worth the investment.
A set of brightly printed cotton bedsheets so you can add a vibrant summer vibe to your bed while you escape from the grueling summer temps. These get rave reviews for the bold prints that actually look as nice in person as they do in the product photos, and for having a ~crisp~ percale texture that'll give you that *fresh sheet* feeling every night.
A super sweet rainbow set — it's made with 100% cotton, meaning it'll be light and breathable enough to keep kids (or your inner child) comfy and cool all afternoon long, when it's time for a nap, *and* all night long.
A set of cotton sheets that'll combine your love for bold, vibrant patterns and breathable fabrics, thanks to the percale weave. The fitted sheet can easily fit mattresses up to 18 inches deep, so they might just make you dread sheet-changing-day a little less.
Or a cotton set featuring a super vibrant red floral pattern so you can make it look like spring every single day of the year. The breathable percale weave will also make it feel like spring too — not too cold, not too hot.
Or! A 100% cotton set made with a smooth sateen weave that'll drape super elegantly over your bed and basically turn it into a work of art. Reviewers say they hold up for years, and some have even picked up extra sets!
A chic set made with 100% stone-washed linen — come for the lightweight softness, stay for the dramatic flair of the ruffled pillowcases.
An absolutely adorable set made with 100% cotton and a percale weave — the coffee that's printed on them might be hot, but you'll stay as cool as a glass of cold brew. No judgment if they inspire you to have breakfast-in-bed and leave croissant crumbs all over them. It'll just elevate the vibe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Business Wire

time3 hours ago

  • Business Wire

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. 'With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.' 'Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective,' concluded Drysdale. Recent Business and Pipeline Highlights: Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose. Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study. Clinical Program Summary CYB003: Deuterated psilocin program Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 2026 1. CYB003 program accomplishments: Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD. A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months: 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. CYB004: Deuterated dimethyltryptamine program The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month 1. Change in Presentation Currency Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar (' USD '). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated. First-Quarter Financial Highlights Cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year. Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Note: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.

StatLab Empowers Growth in Key European Countries through Direct Market Expansions in Germany and France
StatLab Empowers Growth in Key European Countries through Direct Market Expansions in Germany and France

Business Wire

time10 hours ago

  • Business Wire

StatLab Empowers Growth in Key European Countries through Direct Market Expansions in Germany and France

MCKINNEY, Texas--(BUSINESS WIRE)--StatLab Medical Products ('StatLab'), a leading global developer and manufacturer of medical diagnostic supplies and equipment, today announced the completed acquisitions of Germany-based histology service and distribution company Histoserve GmbH ('Histoserve') as well as Diapath France SAS ('Diapath France'). These moves mark a significant step forward in StatLab's European growth strategy, expanding its direct commercial presence to the top four European markets: France, Germany, Italy, and the UK, a milestone that positions StatLab among the few suppliers with fully direct access to Europe's largest pathology markets, enabling closer customer relationships and expanded access to StatLab's full product portfolio. This milestone positions StatLab among the few suppliers with direct access to Europe's largest pathology markets, enabling closer customer relationships and expanded access to StatLab's full product portfolio. Share Founded by Wolfgang Jakobi in 2010 near Hannover, Germany, Histoserve has evolved into a comprehensive solutions provider for pathology labs, providing reliable reagents, innovative instrumentation through Diapath, and best-in-class post-sales support. Diapath made a strategic majority investment in Histoserve in 2021 to create a regional hub and direct market access in Germany. With deep equipment service expertise and strong customer ties, Histoserve will play a critical role in expanding market access to the entire StatLab portfolio in Europe's largest market. In parallel, StatLab acquired the remaining stake in Diapath France—a joint venture formed in 2023 between Diapath and Jacques Hannaby to serve the direct laboratory market in France. These additions strengthen StatLab's direct footprint and future scalability in France and Germany while complementing its already established presence in the UK and Italy, and provide the platform to create an industry leader across the four largest European markets and beyond. 'We're thrilled to officially welcome Histoserve and Diapath France into the StatLab family,' said Alberto Battistel, Managing Director of Diapath. 'Although we've collaborated with Wolfgang and Jacques for several years, fully integrating their businesses into our European strategic plan will further strengthen customer relationships and fuel additional growth.' 'The evolution of the StatLab organization has been exciting to witness, and we're proud to now be a full part of their differentiated solution as a result of the completed acquisition,' said Wolfgang Jakobi, founder of Histoserve. 'Our customers will gain access to a broader product portfolio, and together we'll deliver a more unified customer experience, supporting growth with direct labs across Germany and Northern Europe.' About StatLab Medical Products StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. We offer an extensive portfolio of self-manufactured consumables and equipment from nine manufacturing sites across the United States, United Kingdom, and Europe. Our global operational footprint powered by over 800 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction. About Histoserve Established in Celle, near Hannover, Germany, Histoserve GmbH has delivered decades of histology equipment service—including installation, maintenance, repair, and supply of new and refurbished instruments. With ISO 9001-certified support and a long-standing customer base across Germany and Northern Europe, the company now joins the StatLab family via Diapath to expand its direct-lab service and equipment portfolio.

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Yahoo

time14 hours ago

  • Yahoo

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store